Gilead’s experimental pill emvistegrast beat placebo by 23 percentage points on ulcerative colitis remission in a Phase 2 trial, but long-term data are pending.
Gilead’s Experimental Ulcerative Colitis Pill Beat Placebo by 23 Points on Remission, but Long-Term Safety Data Are Pending
by | Oct 21, 2026 | Uncategorized | 0 comments
Recent Comments